摘要
观察依达拉奉右坎醇联合尤瑞克林注射液治疗穿支动脉病变型进展性脑梗死的疗效及对患者脑缺血区血流量和血清脂蛋白磷脂酶A2(Lp-PLA2)、微小RNA-126(miR-126)的影响。选取2019年2月至2022年12月收治的90例穿支动脉病变型进展性脑梗死患者为对象,采用信封法随机分为对照组(n=42)和观察组(n=48)。两组均给予常规治疗,对照组在常规基础上联合尤瑞克林注射液治疗,观察组在常规基础上给予依达拉奉右坎醇和尤瑞克林注射液治疗。比较两组相关血清因子及评分的变化,检测两组脑血流差异,统计两组安全性。两组治疗前血清Lp-PLA2、神经元特异性烯醇化酶(NSE)、β淀粉样蛋白1-42(Aβ1-42)、miR-126比较,无统计学差异(P>0.05)。与治疗前比较,两组治疗后血清Lp-PLA2、NSE、Aβ1-42降低,且观察组低于对照组(P<0.01)。两组血清miR-126升高,且观察组高于对照组(P<0.01)。两组治疗前脑血流比较,无统计学差异(P>0.05)。与治疗前比较,两组治疗后大脑中动脉和后动脉Vm升高,且观察组高于对照组(P<0.01)。两组大脑中动脉和后动脉PI降低,且观察组低于对照组(P<0.01)。两组治疗前相关评分比较,无统计学差异(P>0.05)。与治疗前比较,两组治疗后Barthel指数升高,且观察组高于对照组(P<0.01)。两组美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(mRS)评分降低,且观察组低于对照组(P<0.01)。观察组总不良反应为10.42%(5/48)与对照组的9.52%(4/42)比较,无统计学差异(P>0.05)。依达拉奉右坎醇联合尤瑞克林注射液治疗穿支动脉病变型进展性脑梗死可改善脑缺血区血流量,调节血清Lp-PLA2、miR-126等的表达,改善预后。
This study was to observe the efficacy of edaravone dexcanol combined with Eurekline injection in the treatment of progressive cerebral infarction with perforator artery lesions,and the effects of Edaravone dexcanol on blood flow and serum lipoprotein phospholipase A2(Lp-PLA2)and micrornA-126(miR-126)in patients with cerebral ischemia.Therefore,90 patients with progressive cerebral infarction with perforator artery lesions treated from February 2019 to December 2022 were selected as the objects,and randomly divided into control group(n=42)and observation group(n=48)by envelope method.Both groups were given conventional treatment,the control group was given combined treatment with Ureicrin injection on the basis of routine,and the observation group was given edaravone dexcanol and Ureicrin injection on the basis of routine treatment.The changes of relevant serum factors and scores between the two groups were compared,the differences of cerebral blood flow between the two groups were detected,and the safety of the two groups was analyzed.There were no significant differences in serum Lp-PLA2,neuron-specific enolase(NSE),beta-amyloid 1-42(Aβ1-42)and miR-126 between the two groups before treatment(P>0.05).Compared with before treatment,the serum Lp-PLA2,NSE and Aβ1-42 in two groups were decreased after treatment,and the observation group was lower than the control group(P<0.01).Serum miR-126 was increased in the two groups,and the observation group was higher than the control group(P<0.01).There was no significant difference in forebrain blood flow between the two groups(P>0.05).Compared with before treatment,the Vm of middle cerebral artery and posterior cerebral artery increased in both groups after treatment,and the Vm of observation group was higher than that of control group(P<0.01).Middle and posterior cerebral artery PI decreased in both groups,and the observation group was lower than the control group(P<0.01).There was no significant difference in relevant scores between the two groups before treatment(P>0.
作者
王年臻
周治平
肖成业
WANG Nian-zhen;ZHOU Zhi-ping;XIAO Cheng-ye(Department of Neurology,Haikou Afiliated Hospital of Central South University Xiangya School of Medicine,Haikou 570208,China)
出处
《药物生物技术》
CAS
2023年第6期609-613,共5页
Pharmaceutical Biotechnology
关键词
依达拉奉右坎醇
尤瑞克林注射液
穿支动脉病变
进展性脑梗死
血流量
预后
sEdaravone dexcanol
Ureicrin injection
Perforating artery disease
Progressive cerebral infarction
Blood flow
Prognosis
